Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2011-08-16
2011-08-16
Desai, Anand (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S345000, C530S402000, C514S002600
Reexamination Certificate
active
07999067
ABSTRACT:
The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes formed by self-assembling peptides and then implanted at sites of tissue damage to help promote repair.
REFERENCES:
patent: 5563048 (1996-10-01), Honjo et al.
patent: 5670483 (1997-09-01), Zhang
patent: 5756084 (1998-05-01), Honjo et al.
patent: 6214540 (2001-04-01), DiVico et al.
patent: 6548630 (2003-04-01), Zhang
patent: 6852508 (2005-02-01), Hermann et al.
patent: 6875738 (2005-04-01), Clark-Lewis et al.
patent: 6946445 (2005-09-01), Clark-Lewis et al.
patent: 7354899 (2008-04-01), Clark-Lewis et al.
patent: 7378098 (2008-05-01), Tudan et al.
patent: 7435718 (2008-10-01), Tudan et al.
patent: 7547674 (2009-06-01), Anversa et al.
patent: 7662392 (2010-02-01), Itescu
patent: 2002/0094327 (2002-07-01), Petersen
patent: 2002/0107195 (2002-08-01), Gupta
patent: 2002/0107196 (2002-08-01), Gupta
patent: 2002/0111290 (2002-08-01), Homey et al.
patent: 2002/0156023 (2002-10-01), Walling et al.
patent: 2002/0165123 (2002-11-01), Tudan et al.
patent: 2003/0199464 (2003-10-01), Itescu
patent: 2003/0215792 (2003-11-01), Muller et al.
patent: 2004/0037811 (2004-02-01), Penn et al.
patent: 2004/0247564 (2004-12-01), Itescu
patent: 2005/0020528 (2005-01-01), Herrmann et al.
patent: 2005/0059584 (2005-03-01), Merzouk et al.
patent: 2005/0142101 (2005-06-01), Forssmann et al.
patent: 2005/0271639 (2005-12-01), Penn et al.
patent: 2006/0088510 (2006-04-01), Lee et al.
patent: 2006/0110374 (2006-05-01), Czeiger et al.
patent: 2006/0148703 (2006-07-01), Lee et al.
patent: 2007/0060512 (2007-03-01), Sadeghi et al.
patent: 2007/0203062 (2007-08-01), Ellis-Behnke et al.
patent: 2007/0224171 (2007-09-01), Penn et al.
patent: 2007/0258943 (2007-11-01), Penn et al.
patent: 2008/0253996 (2008-10-01), Boschert et al.
patent: 02/38172 (2002-05-01), None
patent: 2004/017978 (2004-03-01), None
patent: 2004/094465 (2004-11-01), None
patent: 2006/074464 (2006-07-01), None
patent: 2006/124013 (2006-11-01), None
patent: 2007/079460 (2007-07-01), None
Heveker et al. (2001) Pharmacological properties of peptides derived from stromal cell-derived factor 1: study on human polymorphonuclear cells, Mol. Pharmacol., vol. 59, No. 6, pp. 1418-1425.
Askari, et al., “Effect of Stromal-Cell-Derived factor 1 on stem-cell homing and tissue regeneration in ischemic cardiomyopathy,” Lancet 362:697-703 (Aug. 2003).
Carr, A.N. et al., Cardiovascular research, 69:925-935 (2006). “Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: Support for an endothelium-dependent mechanism.”
Chen, et al., “Site Specific Labeling of Cell Surface Proteins With Biophysical Probes Using Biotin Ligase,” Nature Methodr 2(2):99-104 (Feb. 2005).
Cosset, F. L et al., Journal of Virology, 69(12):7430-7436 (1995). “High-titer packaging cells producing recombinant retroviruses resistant to human serum.”
Crump, et al., “Solution Structure and Basis for Functional Activity of Stromal Cell-Derived Factor-I; Dissociation of CXCR4 Activation from binding and Inhibition of HIV-I,” EMBO J. 16:6996-7007 (1997).
Davis, et al., “Local Myocardial Insulin Like growth Factor 1 (IGF-I)delivery with Biotinylated Peptide Nanofibers Improves Cell Therapy for Myocardial Infarction,” Proc. Nat'l Acad. Sci. USA 103(21): 8155-8160 (May 2006).
Elambdough, I. et al., Journal of Moiecular and Cellular Cardiology, 42:792-803 (2007). Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted mycardium.
Gallagher, et al., “Diabetic Impairments in NO-Mediated Endothelial Progenitor Cell Mobiiization and Homing are Reversed by Hyperoxia and SDF-1A,” J. Clin. Invest. 117(5):1249-1259 (May 2007).
Heveker, et al. (2001) Pharmacological properties of peptides derived from stromal cell-derived factor 1: study on human polymorphonuclear cells, Mol. Pharmacol., vol. 59, No. 6, pp. 1418-1425.
Hiasa, K. et al., Circulation, 109:2454-2461 (2004). “Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway.”.
Hsieh, el at., “Controlled Delivery of PDGF-BB for Myocardial Protection Using Injectable Self-Assembling Peptide Nanofibers,” J. Clin. Invest. 116(1):237-248 (Jan. 2006).
Koch, K.C. et al, Basic Res Cardiol, 100:1-9 (2005). “Effect of catheter-based transendocardial delivery of stromal cell-derived factor 1alpha on left ventricular function and perfusion in a porcine model of myocardial infarction.”
Lapidot, et al.,“How Do Stem Cells Find Their Way Home?” Blood 106(6)1901-1910 (Sep. 2005).
Loetscher et al. (1998) N-terminal peptides of stromal cell-derived factor-1 with CXC chemokine receptor 4 agonist and antagonist activities, J. Biol. Chem., vol. 213, No. 35, pp. 22279-22283.
Medical Technology 3-DM Inc. Products, Introduction, Puramatrix [cited Aug. 4.2009] Access: http//www.puramatix.com/pr01,html.
Mirshahi et al. (2000) SDF-1 activity on microvascular endothelial cells; consequences on angiogenesis in in vitro and in vivo models, Thromb. Res., vol. 99, No. 6, pp. 587-594.
Nagasawa, et al., “Defects of B-Cell Lymphopoiesis and Bone-Marrow Myelopoiesis in Mice Lacking the CXC Chemokine PGSF/SDF-1,” Nature 382:635-638 (Aug. 1996).
Netzel-Arnett, S. et al., Biochemistry, 32:6427-6432 (1993). Comparative sequence specificit es of human 72-and 92-kDa gelatinases (Type IV collagenases) ans PUMP (Matrilysin).
Penn, et al., “Role of Stem Cell Homing in Myocardial Regeneration,” Int. J. Cardiol. 95(Suppl. I): S23-S25 (2004).
Pillarisetti, et al., “Cloning and relative expression Analysis of rat Stromal Cell Derived Factor-1 (SDF-1)1: SDF-1 alpha mRNA is Selectively Induced in Rat Model of Myocardial Infarction,” Inflammation 25(5):293-300 (Oct. 2001).
Sasaki, T. et al., Pediatrics International, 49:966-971 (2007). “Stromal cell-derived factor-1alpha improves infarcted heart function through angiogenesis in mice.”.
Saxena, E. et al., Circulation 117:2224-2231 (2008). “Stomal cell-derived factor-1 alpha is cardioprotective after myocardial infarction.”.
Segers et al. (Oct. 2007) Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction, Circulation, vol. 116, No. 15, pp. 1683-1692.
Shioda, T. et al., Proc. Natl. Acad. Sci. USA, 95:63331-6336 (1998). “Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-lalpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage.”
Yamaguchi, J. et al., Circulation, 107:1322-1328 (2003). “Stromal cell-derivved factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment of ischemic neovascularization.”
Zhang. G. et al., Tissue Engineering, 13(8):2063-2071 (2007). “Controlled release of stromal cell-derived factor-1alpha in situ increases C-kit+cell homing to the infarcted heart.”
Zhong, et al. (2004) Small peptide analogs to stromal derived factor-1 enhance chemotactic migration of human and mouse hematopoletic cells, Exp. Hematot, vol. 32, No. 5, pp. 470-475.
Zou et al., “Function of the Chemokine Receptor CXCR4 in Haematopoiesis and Cerebellar development,” Nature 393:595-599 (Jun. 1998).
De La Luz Sierra Maria at al. “Differential processing of stromal-derived factor-1alpha and stromal-derived factor-1beta explains functional diversity,” Blood, American Society of Hematology, 103(7):2452-2459 (2004).
Kryczek Ilona at al. “Stroma-derived factor (SDF-1/CXCL12) and human tumor path
Lee Richard T.
Segers Vincent
Desai Anand
Liu Samuel
Nixon & Peabody LLP
The Brigham and Women's Hospital, Inc.
LandOfFree
Protease resistant mutants of stromal cell derived factor-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protease resistant mutants of stromal cell derived factor-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protease resistant mutants of stromal cell derived factor-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2632486